[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588244":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":36,"locations":43,"responsibleParty":60,"collaborators":41,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":41,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":41,"studyType":75,"phases":76,"briefSummary":79,"conditions":80,"keywords":41,"overallStatus":46,"whyStopped":41,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1 Dose Escalation","EXPERIMENTAL","ZG005 will be given 10mg\u002Fkg or 20mg\u002Fkg or other dose every three weeks and ZGGS18 will be given 10 mg\u002Fkg every three weeks",[13,14],"Biological: ZGGS18 for Injection","Biological: ZG005 for Injection",{"label":16,"type":10,"description":17,"interventionNames":18},"Phase 2 Dose Expansion","ZG005 will be given RP2D every three weeks and ZGGS18 will be given 10 mg\u002Fkg every three weeks",[13,14],[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","ZGGS18 for Injection","Intravenous infusion",[9,16],[26],"ZGGS18",{"type":21,"name":28,"description":23,"armGroupLabels":29,"otherNames":30},"ZG005 for Injection",[9,16],[31],"ZG005",[33],{"name":34,"affiliation":5,"role":35},"Jason Wu","STUDY_CHAIR",[37],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Siqi Jia","CONTACT","+86-0512-57018310",null,"jiasy@zelgen.com",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":41,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Sun Yat-sen University Cancer Center","RECRUITING","Guangzhou","Guangdong","China","CN",{"type":52,"coordinates":53},"Point",[54,55],113.25,23.11667,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":41,"phoneExt":41,"email":41},"Li Zhang",{"type":61,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100588244","phase-1-study-of-zggs18-in-combination-with-zg005-in-patients-with-advanced-solid-tumors-100588244",false,"NCT06938880","Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors","A Phase I\u002FII Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors, Including Cervical Cancer, Hepatocellular Carcinoma, Neuroendocrine Tumors, and Lung Cancer","Inclusion Criteria:\n\n* Fully understand this study and voluntarily sign the ICF.\n* Age 18-75 years, no gender restriction.\n* Patients with advanced solid tumors who have failed standard treatment or are intolerant to standard treatment, as confirmed by histopathology or cytology.\n\nExclusion Criteria:\n\n* Medical history, CT scan, or MRI indicates the presence of CNS metastases.\n* Other malignancies within 5 years.\n* Any other reason deeming the participant unsuitable for the study, as judged by the investigator.","ALL","18 Years","75 Years",{"count":73,"type":74},60,"ESTIMATED","INTERVENTIONAL",[77,78],"PHASE1","PHASE2","This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.",[81],"Advanced Solid Tumor","2025-12-30",{"date":84,"type":85},"2026-01-05","ACTUAL",{"date":87,"type":85},"2025-05-20",{"date":89,"type":74},"2028-04",{"name":5,"class":6},1]